A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 47, 102619
Abstract
No abstract availableKeywords
Funding Information
- University of Massachusetts (00017442)
This publication has 28 references indexed in Scilit:
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis?Multiple Sclerosis and Related Disorders, 2015
- Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational studyJournal of Neurology, 2015
- Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacyJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Reprogramming the immune repertoire with alemtuzumab in MSNature Reviews Neurology, 2013
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialThe Lancet, 2012
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 2012
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple SclerosisJournal of Clinical Immunology, 2009
- Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohortsJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Rating neurologic impairment in multiple sclerosisNeurology, 1983